Guidance
Considerations for optimizing deployment of ChAdOx1-S [recombinant] vaccines in a time-limited constrained supply situation (AstraZeneca/AZD1222-Vaxzevria, AstraZeneca/SK Bioscience and SII/Covishield vaccines)
Purpose: This document provides an overview of the scientific basis and key programmatic considerations to guide national decision-making for countries on optimizing the deployment of
AstraZeneca/AZD1222 and SII/Covishield vaccines under circumstances where vaccine supply is constrained, and future quantities and delivery dates cannot be reliably predicted. Further details on the available evidence and key studies are available at the SAGE website, while resources for implementation and training are available at the COVID-19 vaccine introduction toolkit webpage.
Authors
Languages
- English
Publication year
2021
Type
Guidance
Categories
- Programme management
Diseases
- COVID-19
Countries
- Chad
